Puma Biotechnology Inc. (PBYI)

12.82
NASDAQ : Health Technology
Prev Close 13.54
Day Low/High 12.81 / 13.56
52 Wk Low/High 13.15 / 65.45
Avg Volume 1.02M
Exchange NASDAQ
Shares Outstanding 38.61M
Market Cap 522.81M
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Puma Biotechnology Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares

Puma Biotechnology Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the underwriters for its public offering of 3,750,000 shares of its common stock at $40.

Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble

Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble

Puma CEO Alan Auerbach wanted the cash desperately, regardless of Puma's stock price. Get the deal done, even if you have to sell it to the shorts.

Puma Biotechnology Prices Public Offering Of Common Stock

Puma Biotechnology Prices Public Offering Of Common Stock

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of $40.

Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering

Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering

Puma Biotechnology (PBYI) is commencing a secondary public offering of stock.

Puma Biotechnology Announces Proposed Public Offering Of Common Stock

Puma Biotechnology Announces Proposed Public Offering Of Common Stock

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it is commencing an underwritten public offering of $150 million of shares of its common stock.

Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Investors Survive Defendants' Motion To Dismiss In Securities Class Action

Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Investors Survive Defendants' Motion To Dismiss In Securities Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that a lawsuit was filed against Puma Biotechnology, Inc.

Biotech Stock Mailbag: Dynavax, Puma, Ariad

Biotech Stock Mailbag: Dynavax, Puma, Ariad

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Puma Biotechnology Shares Leap Forward

Puma Biotechnology Shares Leap Forward

Shares are finally roaring back from big losses in 2014 and 2015.

Why Puma Biotechnology (PBYI) Stock Is Surging Today

Why Puma Biotechnology (PBYI) Stock Is Surging Today

Puma Biotechnology (PBYI) stock was trading sharply higher Tuesday morning after the FDA approved the new drug application for its breast-cancer treatment.

Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the U.

Jim Cramer's Top Takeaways: Salesforce.com, GCP Applied Technologies, Puma Biotechnology

Jim Cramer's Top Takeaways: Salesforce.com, GCP Applied Technologies, Puma Biotechnology

Cramer says he's still a believer in Salesforce and its CEO, Marc Benioff, despite the last quarter's results.

Jim Cramer's 'Mad Money' Recap: What Is Going on With This Market?

Jim Cramer's 'Mad Money' Recap: What Is Going on With This Market?

Cramer said the market is a ball of confusion and he doesn't blame any investor for sitting on the sidelines a while.

Noteworthy Wednesday Option Activity: PBYI, MOV, BOFI

Noteworthy Wednesday Option Activity: PBYI, MOV, BOFI

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Puma Biotechnology, Inc. , where a total volume of 3,028 contracts has been traded thus far today, a contract volume which is representative of approximately 302,800 underlying shares (given that every 1 contract represents 100 underlying shares).

4 Biotech Stock Charts You Must See

4 Biotech Stock Charts You Must See

Biotech stocks dominate our list of top charts today. Here are four to watch.

Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe

Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European Medicines Agency (EMA).

Puma Biotechnology Reports Second Quarter 2016 Financial Results

Puma Biotechnology Reports Second Quarter 2016 Financial Results

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016.

Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs

Biotech Stock Mailbag: Puma Roars, Relypsa Soars, XBiotech Bombs

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Morning Movers: GE, AMD, P, PBYI

Morning Movers: GE, AMD, P, PBYI

General Electic shares dipped as industrial orders waned in the second quarter.

Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)

Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of...

Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has submitted a New Drug Application (NDA) to the U.

Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine

Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the positive results from the I-SPY 2 Phase II clinical trial of neratinib for the neoadjuvant treatment of breast cancer were published in...

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

'Mad Money' Lightning Round: I Like Sirius XM Radio

'Mad Money' Lightning Round: I Like Sirius XM Radio

Cramer is taking Southwest Airlines over United Continental while Palo Alto Networks is good value but not great.

Jim Cramer's 'Mad Money' Recap: Add These 2 Stocks to FANG

Jim Cramer's 'Mad Money' Recap: Add These 2 Stocks to FANG

Three of Cramer's four FANG stocks still perform but the fourth can easily be replaced by these two companies.

Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe

Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for neratinib.

August 19th Options Now Available For Puma Biotechnology (PBYI)

August 19th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the August 19th expiration.

Short Interest Increases 11.8% For PBYI

Short Interest Increases 11.8% For PBYI

The most recent short interest data has been released for the 05/31/2016 settlement date, which shows a 530,564 share increase in total short interest for Puma Biotechnology, Inc. , to 5,028,719, an increase of 11.80% since 05/13/2016.

Puma Biotechnology Presents Positive Phase II Data At The 2016 ASCO Annual Meeting

Puma Biotechnology Presents Positive Phase II Data At The 2016 ASCO Annual Meeting

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator-sponsored Phase II trial of neratinib with HER2-mutated, non-amplified breast cancer.

Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting

Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO)...

TheStreet Quant Rating: D- (Sell)